Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
16 Enero 2024 - 3:05PM
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage
biotechnology company pioneering the development of allogeneic CAR
T (AlloCAR T™) products for cancer and autoimmune disease, today
announced that it will participate in three upcoming investor
conferences in January and February.
B. Riley Oncology ConferenceThursday, January 18,
202412:30PM PT/3:30PM ET
Guggenheim Healthcare Talks 6th Annual Biotechnology
ConferenceWednesday, February 7, 20248:30AM PT/11:30AM ET
Oppenheimer 34th Annual Healthcare Life Sciences
ConferenceWednesday, February 14, 20249:00AM PT/12:00PM ET
Any available webcasts will be posted to the Company's website
at www.allogene.com under the Investors tab in the News and
Events section. Following a live webcast, a replay will be
available on the Company's website for approximately 30 days.
About Allogene TherapeuticsAllogene
Therapeutics, with headquarters in South San Francisco, is a
clinical-stage biotechnology company pioneering the
development of allogeneic chimeric antigen receptor T cell
(AlloCAR T™) products for cancer and autoimmune disease. Led by a
management team with significant experience in cell therapy,
Allogene is developing a pipeline of “off-the-shelf” CAR T cell
product candidates with the goal of delivering readily
available cell therapy on-demand, more reliably, and
at greater scale to more patients. For more information,
please visit www.allogene.com, and follow @AllogeneTx on X
(formerly Twitter) and LinkedIn.
Cautionary Note on Forward-Looking Statements for
AllogeneThis press release contains forward-looking
statements for purposes of the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. Forward-looking
statements include statements regarding intentions, beliefs,
projections, outlook, analyses or current expectations concerning,
among other things Allogene’s ability to develop and deliver
readily available allogeneic CAR T products for cancer treatment
on-demand, more reliably, and at greater scale to more patients.
Various factors may cause material differences between Allogene’s
expectations and actual results, including risks and uncertainties
related to our product candidates are based on novel technologies,
which makes it difficult to predict the time and cost of product
candidate development, the safety or efficacy of a product
candidate, and whether a product candidate will receive regulatory
approval, which could prevent or delay commercialization. These and
other risks are discussed in greater detail in Allogene’s filings
with the SEC, including without limitation under the “Risk Factor”
Heading in its Form 10-Q filed for the quarter ended September 30,
2023. Any forward-looking statements that are made in this press
release speak only as of the date of this press release. Allogene
assumes no obligation to update the forward-looking statements
whether as a result of new information, future events or otherwise,
after the date of this press release.
AlloCAR T™ is a trademark of Allogene Therapeutics, Inc.
Allogene Media/Investor Contact:Christine
CassianoEVP, Chief Corporate Affairs & Brand Strategy
OfficerChristine.Cassiano@allogene.com
Allogene Therapeutics (NASDAQ:ALLO)
Gráfica de Acción Histórica
De Ago 2024 a Sep 2024
Allogene Therapeutics (NASDAQ:ALLO)
Gráfica de Acción Histórica
De Sep 2023 a Sep 2024